Literature DB >> 20920714

Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children.

Christopher R Frei1, Brittany R Makos, Kelly R Daniels, Christine U Oramasionwu.   

Abstract

BACKGROUND: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) was first observed in pediatric patients in the late 1990s. Since then, possible risk factors for contracting CA-MRSA have been hypothesized, but supporting studies are limited.
METHODS: We analyzed hospital discharge records for patients with a principal International Classification of Diseases, Ninth Revision code for skin and soft tissue infections, collected from 1996 to 2006 by the United States National Center for Health Statistics. Noninstitutional, short-stay hospitals in the United States participated. The sample was limited to patients aged ≤19 years. Staphylococcus aureus and CA-MRSA were defined by International Classification of Diseases, Ninth Revision codes. Data weights were used to derive regional and national estimates. Population estimates were obtained from the US Bureau of the Census, and incidence rates were reported per 100,000 persons. Risk factors for CA-MRSA were first identified using χ(2) and χ(2) goodness-of-fit tests, then by multivariable logistic regression.
RESULTS: These data represent 616,375 pediatric discharges for skin and soft tissue infections from U.S. hospitals between 1996 and 2006. This represents approximately 69.9 hospitalizations for skin and soft tissue infections per 100,000 U.S. children per year. Staphylococcus aureus and CA-MRSA accounted for 19.6% and 9.6% of these cases, respectively. The rate of hospitalization for CA-MRSA skin and soft tissue infections increased dramatically over the study period; from less than one case per 100,000 in 1996 to 25.5 cases per 100,000 in 2006. Rates of CA-MRSA varied by region, with the South region having the highest rate (11.5 per 100,000 US children), followed by the West (5.2), Northeast (3.4), and Midwest (3.2). Peak CA-MRSA incidence occurred from May to December; however, the incidence in the South region was consistently higher than other regions for most months and the period of peak incidence was longer than other regions. Independent risk factors for CA-MRSA included survey year, race, geographic region, hospital size, and health insurance status (P < .0001 for all risk factors).
CONCLUSIONS: Pediatric hospitalizations for methicillin-susceptible S. aureus and CA-MRSA skin and soft tissue infections are on the rise. Possible risk factors for CA-MRSA infection include White race, residence in the South region of the United States, and lack of health insurance.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20920714     DOI: 10.1016/j.jpedsurg.2010.05.009

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  25 in total

Review 1.  Antibacterials as adjuncts to incision and drainage for adults with purulent methicillin-resistant Staphylococcus aureus (MRSA) skin infections.

Authors:  Nicolas A Forcade; Nathan P Wiederhold; Laurajo Ryan; Robert L Talbert; Christopher R Frei
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

2.  Trends in resource utilization for hospitalized children with skin and soft tissue infections.

Authors:  Michelle A Lopez; Andrea T Cruz; Marc A Kowalkowski; Jean L Raphael
Journal:  Pediatrics       Date:  2013-02-25       Impact factor: 7.124

3.  Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use.

Authors:  Fawziah Marra; David M Patrick; Mei Chong; Rachel McKay; Linda Hoang; William R Bowie
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

4.  A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection.

Authors:  Cheryl Y M Okumura; Andrew Hollands; Dan N Tran; Joshua Olson; Samira Dahesh; Maren von Köckritz-Blickwede; Wdee Thienphrapa; Courtney Corle; Seung Nam Jeung; Anna Kotsakis; Robert A Shalwitz; Randall S Johnson; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2012-02-28       Impact factor: 4.599

5.  Differences in methicillin-resistant Staphylococcus aureus strains isolated from pediatric and adult patients from hospitals in a large county in California.

Authors:  Lyndsey O Hudson; Courtney R Murphy; Brian G Spratt; Mark C Enright; Leah Terpstra; Adrijana Gombosev; Paul Hannah; Lydia Mikhail; Richard Alexander; Douglas F Moore; Susan S Huang
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

6.  Impact of Decolonization Protocols and Recurrence in Pediatric MRSA Skin and Soft-Tissue Infections.

Authors:  Steven T Papastefan; Christie Buonpane; Guillermo Ares; Beshoy Benyamen; Irene Helenowski; Catherine J Hunter
Journal:  J Surg Res       Date:  2019-05-06       Impact factor: 2.192

7.  Update on Epidemiology and Treatment of MRSA Infections in Children.

Authors:  Michael Z David; Robert S Daum
Journal:  Curr Pediatr Rep       Date:  2013-09-01

8.  The effect of statin therapy on the incidence of infections: a retrospective cohort analysis.

Authors:  John P Magulick; Christopher R Frei; Sayed K Ali; Eric M Mortensen; Mary Jo Pugh; Christine U Oramasionwu; Kelly R Daniels; Ishak A Mansi
Journal:  Am J Med Sci       Date:  2014-03       Impact factor: 2.378

9.  Trends in adverse reactions to trimethoprim-sulfamethoxazole.

Authors:  Jennifer L Goldman; Mary Anne Jackson; Joshua C Herigon; Adam L Hersh; Daniel J Shapiro; J Steven Leeder
Journal:  Pediatrics       Date:  2012-12-03       Impact factor: 7.124

10.  Clinical characteristics of pediatric patients hospitalized with methicillin-resistant Staphylococcus aureus in Canadian hospitals from 2008 to 2010.

Authors:  Kirk Ryan Leifso; Denise Gravel; Aboubaker Mounchili; Sherif Kaldas; Nicole Le Saux
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.